Group 1 - The A-share market is expected to experience a "New Year opening red" trend due to improved liquidity and exchange rate conditions compared to the previous two years [1][3] - Key sectors to focus on include semiconductors, AI, non-bank financials, new energy, and machinery equipment, with a long-term positive outlook on industrial metals, small metals, and innovative pharmaceuticals [1] - The market sentiment index has risen to 80, indicating high investor enthusiasm, and the "cross-year market" is likely to continue into January [2] Group 2 - The geopolitical tension from the U.S. military action in Venezuela is expected to lead to short-term increases in gold and oil prices, while the long-term impact on international oil prices may be negative [4] - China's heavy reliance on Venezuelan crude oil, which accounts for 80% of its imports, poses risks to certain chemical products due to potential instability in raw material supply [4] - The domestic technology sector, particularly semiconductors and AI chips, is positioned as a core driver of market performance, supported by government policies promoting smart devices and venture capital initiatives [4]

Core Insights - China has achieved record highs in the number of approved innovative drugs and total external licensing transactions, with approximately 30% of global drug pipelines being in development in China [2][4] - The National Medical Products Administration (NMPA) aims to continue promoting innovative drugs with new mechanisms and targets, supported by institutional backing and improvements in the payment system for innovative drugs [2][6] Group 1: Innovative Drug Approvals - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [2] - Among the approved drugs, domestic products accounted for over 85%, with 80.85% of chemical drugs and 91.30% of biological products being domestically developed [3][2] - The number of first-in-class innovative drugs approved in China reached 11, with 4 being independently developed in China [4] Group 2: External Licensing Transactions - The total amount for external licensing transactions of innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, doubling from the previous year [6] - This growth reflects international recognition of the value of Chinese innovative drugs and is supported by ongoing reforms in drug review and approval processes [6][8] Group 3: R&D Pipeline and Quality - China's R&D pipeline now accounts for about 30% of the global total, a significant increase from just 4% a decade ago [4] - The quality of domestic drug development has improved, with contributions to early clinical pipelines for next-generation therapies like ADCs and bispecific/trispecific antibodies nearing or exceeding 50% globally [4] Group 4: Policy and Market Dynamics - The NMPA plans to enhance support for urgently needed drugs and improve the regulatory framework for drug trials and market exclusivity [7][8] - The introduction of the commercial insurance innovative drug directory is expected to facilitate access to high-priced innovative drugs, potentially boosting market sales [9] - The Chinese innovative drug market is projected to grow significantly, with estimates suggesting a market size of approximately 740 billion RMB in 2025 and a compound annual growth rate of 24.1% from 2024 to 2030 [10]

Core Viewpoint - The report from CITIC Securities indicates that the biggest expected divergence in 2026 will stem from the balance between external and internal demand, with a trend towards imposing tariffs on external demand and subsidizing internal demand, marking an important beginning this year [1][7]. Market Overview - The market is expected to experience a higher probability of upward movement after the New Year, given the relatively low funding enthusiasm at the end of last year and the prevailing sentiment of wanting to see market growth [1][8]. - The overall market sentiment is currently restrained, with many investors waiting for the right entry point, suggesting limited potential for significant market corrections in the absence of major unexpected risks [8]. Investment Strategy - The company recommends adopting a mindset focused on "earning performance money rather than expecting valuation money" for mid-term investments, favoring sectors with lower heat and concentration but increasing attention and catalysts, such as chemicals, engineering machinery, electric power equipment, and new energy [1][10]. - There is a cautious approach towards high prosperity and high heat sectors that have seen stagnant stock prices, while new industry themes like commercial aerospace are expected to continue to evolve and warrant ongoing attention [1][10]. Performance Analysis - In 2025, the median return for actively managed public funds tracked by CITIC Securities was 28.2%, ranking third over the past decade, with a significant disparity in returns between the top and bottom deciles [2]. - The overall performance of the A-share and Hong Kong stock markets in 2025 can be divided into five phases, with notable fluctuations driven by external factors such as tariff impacts and AI application narratives [3][4]. Structural Market Dynamics - The significant money in the structural bull market in 2025 primarily came from the correction of expected divergences and performance growth, particularly in the context of external and internal demand dynamics [4]. - The report highlights that the market's perception of external demand has shifted from optimism to caution, with geopolitical factors influencing expectations throughout the year [7]. Future Outlook - The anticipated structural adjustments in trade policies, including increased tariffs and stricter export controls, indicate a shift in China's approach to external trade, aiming to balance external and internal demand [7]. - The report emphasizes that the market may struggle to quickly price in these significant structural changes, which could serve as both a source of expected divergence and potential performance growth [7].

Core Viewpoint - The market is experiencing a structural bull market driven by a significant re-evaluation of China's technological capabilities and the complexities of US-China relations, alongside resilient external demand and an explosion in AI inference demand [1][2][3] Group 1: Market Performance and Expectations - In 2025, the median return of actively managed public funds is projected to be 28.2%, ranking third in the past decade and sixth in the last twenty years [1][12] - The overall market performance can be divided into five phases, with the total return of the CSI All A Shares Index at 27.7% and the Hang Seng Tech Index at 23.4% for the year [2][13] - The first phase shows a brief market excitement before the Spring Festival, while the second phase sees a significant rally in the Hang Seng Tech Index due to a shift in narrative regarding China's autonomous technology [2][13] Group 2: Structural Bull Market Dynamics - The "big money" in the structural bull market comes from substantial expected differences and performance growth, primarily driven by the correction of pessimistic expectations regarding external demand and the AI industry's evolution [3][14] - The market's perception of external demand shifted from pessimism to optimism throughout the year, culminating in a consensus on external demand exposure by year-end [3][14] - The AI industry's demand surge has filled gaps during transitional phases, leading to significant valuation recoveries for key companies [4][14] Group 3: Liquidity and Market Dynamics - Incremental liquidity is viewed as a result of the expected difference and performance realization, rather than a primary driver of market growth [5][15] - The net inflow of ETFs was 230.6 billion yuan for the year, indicating that liquidity does not directly correlate with market index increases [5][15] - The market is not lacking in funds but rather in investable assets and imaginative space [5][15] Group 4: Future Expectations and Strategies - The largest expected difference for 2026 will stem from balancing external and internal demand, with a trend towards taxing external trade and subsidizing domestic demand [6][16] - The market sentiment at the end of 2025 was relatively restrained, suggesting a higher probability of upward market movement in early 2026 [7][17] - Investment strategies should focus on sectors with lower heat and concentration but increasing attention and catalysts, such as chemicals, engineering machinery, and renewable energy [9][19]

Investment Rating - The report indicates a positive outlook for the biopharmaceutical industry, highlighting the approval of approximately 101 innovative drugs in 2025, marking a significant growth in the sector [3]. Core Insights - The innovative drug sector in China is experiencing robust growth, with 63 domestic innovative drugs (62% of total approvals) and 38 imported innovative drugs (38% of total approvals) approved in 2025 [3]. - The report suggests several companies to watch, including those with high certainty for overseas expansion and those with potential overseas data catalysts [2][20]. - The report emphasizes the importance of upcoming catalysts such as academic conferences and data releases that could impact the sector positively [2]. Summary by Sections Weekly New Drug Market Review - From December 29, 2025, to January 4, 2026, the top five gainers in the new drug sector were Youzhiyou (+12.45%), Aidi Pharmaceutical (+8.07%), Yongtai Biological (+6.72%), Kaituo Pharmaceutical (+6.25%), and Yahong Pharmaceutical (+4.07%). The top five losers were Jakes (+-15.53%), Yunding Xinyao (-15.06%), Kedi (-11.73%), Gelei Pharmaceutical (-8.64%), and Kangning Jere (-8.06%) [1][16]. Weekly Focused Stocks - The report recommends focusing on companies with MNC certification and high certainty for overseas volume, such as Sanofi Pharmaceutical, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts like Betta Pharmaceuticals and Hengrui Medicine [2][20]. Weekly New Drug Industry Analysis - The report notes that 2025 saw a record high in the number of approved innovative drugs in China, with a total of approximately 101 drugs approved by NMPA, excluding new indications, modified new drugs, biosimilars, traditional Chinese medicine, and vaccines [3][21]. Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved this week, but four new drug or new indication applications were accepted [4][27]. Weekly New Drug Clinical Application Approval & Acceptance - This week, 18 new drug clinical applications were approved, and 52 new drug clinical applications were accepted [5][30].

Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historic high for the country [1][2] - The total value of innovative drug licensing transactions from China exceeded $130 billion in 2025, with over 150 transactions, also a record high [1][4] - Domestic innovative drugs accounted for over 85% of the newly approved drugs in 2025, indicating a strong growth in local pharmaceutical development [2][3] Group 1: Drug Approval and Market Dynamics - The National Medical Products Administration (NMPA) reported that 38 out of 47 chemical drugs approved in 2025 were domestically developed, representing 80.85% of the total [1] - Among the 23 biological products approved, 21 were domestic, accounting for 91.30% [1] - The number of innovative drugs in the pipeline in China represents approximately 30% of the global total, positioning China as the second-largest contributor worldwide [2] Group 2: International Recognition and Investment - The significant increase in licensing transactions reflects international recognition of the value of Chinese innovative drugs, with the total transaction amount doubling from the previous year [4] - The NMPA is committed to enhancing the approval process for urgently needed drugs, particularly those with new mechanisms and targets, to further stimulate innovation [5] - New policies encouraging foreign investment in the pharmaceutical sector signal China's openness to global capital in drug innovation [5] Group 3: Market Growth and Future Projections - The Chinese innovative drug market is projected to reach approximately 740 billion RMB in 2025, with an overall growth rate of about 35% [7] - By 2030, the market size is expected to exceed 2 trillion RMB, with a compound annual growth rate of 24.1% from 2024 to 2030 [7] - The introduction of the commercial insurance innovative drug directory is anticipated to enhance market access for high-priced innovative drugs, potentially increasing sales [6]

Core Insights - In 2025, southbound capital recorded a net purchase of 14,048.44 billion HKD, marking a historical high and a 73.89% increase from 2024 [1] - The total net inflow of southbound capital since the launch of the Shanghai-Hong Kong Stock Connect has exceeded 51,000 billion HKD [1] - By the end of December, the market value of shares held by southbound capital reached 61,408.83 billion HKD, accounting for over 12% of the total market capitalization of Hong Kong stocks [1] Monthly Trends - Throughout 2025, there were 8 months where net purchases by southbound capital exceeded 1,000 billion HKD, with September seeing the highest net purchase of 1,885.18 billion HKD [1] - The first quarter of 2025 saw a strong performance in the Hong Kong stock market, with the Hang Seng Index rising by 15.25% and the Hang Seng Tech Index increasing by 20.74% [1] Institutional Insights - Multiple institutions indicate that southbound capital is becoming a core force in reshaping the Hong Kong stock market landscape, transitioning from speculative traders to a pricing anchor [3] - Under the backdrop of domestic and international interest rate cuts, it is expected that southbound capital will maintain a net inflow trend into 2026 [3] Active Stocks - In 2025, 137 stocks were listed as active trading stocks, with Alibaba-W leading in total trading volume at 18,779.65 billion HKD [4] - Eight stocks received net purchases exceeding 10 billion HKD from southbound capital, primarily technology leaders, with Alibaba-W netting 1,778.69 billion HKD [4] Stock Performance - Alibaba-W achieved a cumulative increase of 78.6% in 2025, marking its highest annual growth since listing, while its revenue for Q3 2025 was reported at 247.795 billion RMB, a 5% year-on-year increase [4] - Meituan-W, despite a cumulative decline of 31.91% in 2025, still saw a net purchase of 732.99 billion HKD from southbound capital [5] Industry Insights - By the end of 2025, the top three industries by market value held by southbound capital were financials, information technology, and consumer discretionary, with values of 15,703.51 billion HKD, 11,791.08 billion HKD, and 9,961.09 billion HKD respectively [7] - The materials and healthcare sectors experienced the fastest growth in market value, with increases of 238.92% and 125.51% respectively, driven by rising prices of metals and the growing demand for innovative drugs [7][8]

Policy Guidance - The policy environment has shifted from encouraging innovation to systematic and precise guidance on "how to innovate," providing a supportive framework for projects with original innovation capabilities[9] - Over 300 national and local policies related to innovative drugs and supply chains were issued from January to October 2025, with a notable increase in policy density in October alone[18] - The National Medical Products Administration (NMPA) has published over 80 technical guidelines covering various stages from R&D to post-marketing monitoring, focusing on patient-centered approaches and unmet clinical needs[20] Capital Market Trends - The total financing amount in the innovative drug and supply chain sector reached $3.914 billion in the first ten months of 2025, slightly down from 2024 but over 60% of the total for 2023[28] - Capital is increasingly concentrated in later-stage projects (B round and beyond), with B, C, and D rounds collectively accounting for 39% of financing activities[30] - The number of IPOs in the innovative drug sector increased to 19 in the first ten months of 2025, indicating a recovery compared to the previous year[45] Pipeline Competitiveness - 2025 is marked by significant clinical and commercial breakthroughs in China's innovative drug sector, with domestic ADC and bispecific antibody products receiving approvals and showcasing leading clinical data at international conferences[10] - The emergence of new technologies such as CAR-T and TIL therapies is accelerating, with policies supporting their standardized development and addressing accessibility and cost challenges[2] M&A and BD Activities - Over 87 M&A activities occurred globally in the innovative drug sector in 2025, with multinational corporations focusing on acquiring cutting-edge technologies[54] - Domestic M&A activity has slowed compared to 2024, with a focus on internal integration and strategic enhancements by local companies[54]

Investment Rating - The report maintains a "Recommended" rating for several companies in the healthcare sector, including Weili Medical, Zhend Medical, Aohua Endoscopy, and others [33]. Core Insights - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and internationalization for future profitability [11]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is expected to benefit from government subsidies for home medical devices [11][19]. - The life sciences service sector is showing signs of recovery, with increasing demand driven by both domestic and international markets [23]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape [24]. Summary by Sections Market Review - The report notes a 2.02% decline in the CITIC Medical Index, underperforming the CSI 300 Index by 1.44 percentage points, ranking 27th among 30 sectors [7]. Innovative Drugs - The innovative drug sector is expected to see a significant increase in the number of products launched, with projections of over 30 products by 2027, and a revenue share from innovative products expected to exceed 50% by 2025 [15]. Medical Devices - The report identifies a recovery in bidding for imaging devices and highlights the potential for domestic companies to increase market share through product upgrades and international expansion [19][20]. Life Sciences Services - The life sciences service sector is anticipated to benefit from a recovery in overseas demand and an increase in domestic industrial demand, with a focus on mergers and acquisitions to strengthen market positions [23]. Pharmacies - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with recommendations to focus on leading pharmacy chains [24]. Traditional Chinese Medicine - The report emphasizes the importance of basic medicines and state-owned enterprise reforms, suggesting a focus on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [27]. Medical Services - The report recommends focusing on companies with national expansion capabilities in the medical services sector, particularly those in traditional Chinese medicine and ophthalmology [26]. Blood Products - The blood products sector is expected to see growth due to relaxed approval processes for plasma stations and an increase in product offerings [12].

Market Overview - The CITIC Pharmaceutical Index decreased by 2.02%, underperforming the CSI 300 Index by 1.44 percentage points, ranking 27th among 30 primary industries [8] - The top ten stocks with the highest gains this week include Duorui Pharmaceutical, Maillande, and Xiangyu Medical, while the top ten stocks with the largest declines include *ST Changyao and Shuyupingmin [8][37] Overall View and Investment Themes - The domestic innovative drug industry is transitioning from quantity logic to quality logic, emphasizing differentiated and internationalized pipelines, with a focus on products that can generate profits [11] - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, and the home medical device market is benefiting from subsidy policies [11] - The CXO and life sciences services sector is expected to see a rebound in overseas investment and a bottoming out of domestic investment, indicating a potential upturn in the innovation chain [11] - The specialty raw materials pharmaceutical industry is anticipated to experience a new growth cycle, with a focus on the impact of patent expirations on new product volumes [11] Specific Industry Insights Innovative Drugs - The company has significantly increased its pipeline, with the number of innovative products rising from 3 to 18 since 2022, and plans to launch an average of 5 innovative products annually over the next three years [15][16] - The revenue share from innovative products is expected to exceed 50% by 2025, driven by a robust pipeline and strategic partnerships [15][16] Medical Devices - The orthopedic market is projected to grow due to aging demographics and increased surgery penetration, with domestic companies benefiting from the acceleration of local replacements [17] - The IVD market, particularly in chemiluminescence, is expected to grow rapidly, with domestic brands increasing their market share through competitive pricing and improved product offerings [18] Life Sciences Services - The life sciences services sector is recovering, with demand expected to rise in both domestic and overseas markets, driven by increased investment in biopharmaceuticals [24] - The industry is characterized by low penetration rates and a trend towards domestic substitution, with significant opportunities for growth through mergers and acquisitions [24] Traditional Chinese Medicine and Medical Services - The traditional Chinese medicine sector is expected to benefit from policy changes and an aging population, with a focus on unique therapeutic areas and high-dividend stocks [26][31] - The medical services sector is anticipated to improve due to anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private healthcare providers [26] Investment Recommendations - The company recommends focusing on the pharmacy sector due to the acceleration of prescription outflow and the optimization of competitive dynamics, suggesting that the pharmacy sector is poised for recovery [25] - In the medical device sector, attention is drawn to companies that are well-positioned to benefit from domestic substitution and technological advancements [19]